Recent Updates
Recently added Catalysts
TPST

for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-190939) that was filed by the registrant with the Securities and Exchange Commissio

Key Takeaway: The registrant is filing this Exhibit 99.1 for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-190939) that was filed by the registrant with the Securities and Exchange Commission on August 30, 2

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
10.6%
average across 2 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
ATR-101
Phase 2 · Congenital Adrenal Hyperplasia

Full Press Release Details

The registrant is filing this Exhibit 99.1 for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-190939) that was filed by the registrant with the Securities and Exchange Commission on August 30, 2013 and became effective on September 10, 2013.
The following table sets forth the estimated costs and expenses (other than the actual registration fee), other than underwriting discounts and commissions, payable by the registrant in connection with the sale of the securities being registered:
Printing and Engraving Expenses $ 25,000
Legal Fees and Expenses $ 100,000
Accounting Fees and Expenses $ 40,000
Transfer Agent and Registrar Fees $ 5,000
Miscellaneous $ 5,000
Total $ 175,000
Last updated: Mar 6, 2014